Published in AIDS on June 01, 1993
Project Accept (HPTN 043): a community-based intervention to reduce HIV incidence in populations at risk for HIV in sub-Saharan Africa and Thailand. J Acquir Immune Defic Syndr (2008) 3.83
A complex systems approach to evaluate HIV prevention in metropolitan areas: preliminary implications for combination intervention strategies. PLoS One (2012) 1.09
HIV prevalence and factors associated with HIV infection among male injection drug users under 30: a cross-sectional study in Long An, Vietnam. BMC Public Health (2006) 1.03
Large sharing networks and unusual injection practices explain the rapid rise in HIV among IDUs in Sargodha, Pakistan. Harm Reduct J (2009) 0.97
HIV disclosure, condom use, and awareness of HIV infection among HIV-positive, heterosexual drug injectors in St. Petersburg, Russian Federation. AIDS Behav (2011) 0.94
Contraception use and unplanned pregnancies among injection drug-using women in St Petersburg, Russia. J Fam Plann Reprod Health Care (2011) 0.85
Risk Factors for Loss to Follow-Up among People Who Inject Drugs in a Risk Reduction Program at Karachi, Pakistan. A Case-Cohort Study. PLoS One (2016) 0.79
Understanding the effects of different HIV transmission models in individual-based microsimulation of HIV epidemic dynamics in people who inject drugs. Epidemiol Infect (2016) 0.75
Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet (1999) 8.91
HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA (1989) 6.68
HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet (1996) 5.43
Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA (1995) 4.88
Structural interventions: concepts, challenges and opportunities for research. J Urban Health (2006) 4.70
Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS (1987) 3.78
Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users. Ann Intern Med (1985) 3.63
The epidemiology of HIV infection and AIDS in Thailand. AIDS (1991) 3.57
Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. JAMA (1994) 3.41
Sociometric risk networks and risk for HIV infection. Am J Public Health (1997) 3.29
HIV infection among intravenous drug users: epidemiology and risk reduction. AIDS (1987) 3.24
Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health (1995) 3.24
International epidemiology of HIV and AIDS among injecting drug users. AIDS (1992) 3.19
Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav (1988) 3.14
The relevance of drug injectors' social and risk networks for understanding and preventing HIV infection. Soc Sci Med (1994) 3.05
A randomized trial of an interim methadone maintenance clinic. Am J Public Health (1991) 2.99
Network-related mechanisms may help explain long-term HIV-1 seroprevalence levels that remain high but do not approach population-group saturation. Am J Epidemiol (2000) 2.95
AIDS health education for intravenous drug users. Health Educ Q (1986) 2.92
HIV infection and intravenous drug use: critical issues in transmission dynamics, infection outcomes, and prevention. Rev Infect Dis (1988) 2.91
HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health (2000) 2.74
AIDS and self-organization among intravenous drug users. Int J Addict (1987) 2.73
Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. The National AIDS Research Consortium. Am J Epidemiol (1995) 2.66
The AIDS epidemic among blacks and Hispanics. Milbank Q (1987) 2.54
High-risk personal networks and syringe sharing as risk factors for HIV infection among new drug injectors. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 2.38
Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996. Am J Public Health (1998) 2.28
Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Arch Intern Med (2001) 2.25
Effect of HCV, HIV and coinfection in kidney transplant recipients: mate kidney analyses. Am J Transplant (2014) 2.22
Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health (2001) 2.21
A larger spectrum of severe HIV-1--related disease in intravenous drug users in New York City. Science (1988) 2.20
Potential risk factors for the transition to injecting among non-injecting heroin users: a comparison of former injectors and never injectors. Addiction (2001) 2.17
Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. Am J Public Health (2000) 2.09
Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence. Am J Public Health (2001) 2.02
Evaluation of eight methods for identification of pathogenic Neisseria species: Neisseria-Kwik, RIM-N, Gonobio-Test, Minitek, Gonochek II, GonoGen, Phadebact Monoclonal GC OMNI Test, and Syva MicroTrak Test. J Clin Microbiol (1988) 2.01
Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex Transm Infect (2006) 2.00
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
HIV and HCV infection among injecting drug users. Mt Sinai J Med (2000) 1.96
Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Soc Sci Med (1996) 1.93
Fifteen years of research on preventing HIV infection among injecting drug users: what we have learned, what we have not learned, what we have done, what we have not done. Public Health Rep (1998) 1.92
Risk behavior and HIV infection among new drug injectors in the era of AIDS in New York City. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.87
Sleep problems in the community elderly as predictors of death and nursing home placement. J Community Health (1990) 1.84
Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion among individuals with HIV-1 subtype B or E infection in Thailand. AIDS Res Hum Retroviruses (2001) 1.81
Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand. AIDS (2001) 1.80
Harm reduction--a framework for incorporating science into drug policy. Am J Public Health (1995) 1.75
Needle exchange programs for the prevention of human immunodeficiency virus infection: epidemiology and policy. Am J Epidemiol (2001) 1.73
HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. J Acquir Immune Defic Syndr (1999) 1.72
Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs. Am J Public Health (1995) 1.72
Syringe-mediated drug-sharing (backloading): a new risk factor for HIV among injecting drug users. AIDS (1993) 1.72
The epidemic of acquired immunodeficiency syndrome (AIDS) and suggestions for its control in drug abusers. J Subst Abuse Treat (1984) 1.70
Geographic proximity, policy and utilization of syringe exchange programmes. AIDS Care (1999) 1.70
The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials. AIDS (1995) 1.69
Measuring the effects of an international health professions faculty development fellowship: the FAIMER Institute. Med Teach (2010) 1.68
AIDS and the transition to illicit drug injection--results of a randomized trial prevention program. Br J Addict (1992) 1.68
Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months. J Neurol Neurosurg Psychiatry (2009) 1.67
Recommendations for control and prevention of human immunodeficiency virus (HIV) infection in intravenous drug users. Ann Intern Med (1989) 1.65
HIV among drug injectors: the epidemic and the response. AIDS Care (1991) 1.64
Stigmatized drug use, sexual partner concurrency, and other sex risk network and behavior characteristics of 18- to 24-year-old youth in a high-risk neighborhood. Sex Transm Dis (2001) 1.62
Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users. AIDS (1987) 1.60
Hospital utilization patterns and costs for adult sickle cell patients in Illinois. Public Health Rep (1997) 1.60
High compliance with a hepatitis B virus vaccination program among intravenous drug users. J Infect Dis (1991) 1.60
Risk factors and HIV seropositivity among injecting drug users in Bangkok. AIDS (1991) 1.60
HIV-1 subtypes and male-to-female transmission in Thailand. Lancet (1995) 1.59
Harm reduction: a public health response to the AIDS epidemic among injecting drug users. Annu Rev Public Health (1993) 1.57
The protective effect of AIDS-related behavioral change among injection drug users: a cross-national study. WHO Multi-Centre Study of AIDS and Injecting Drug Use. Am J Public Health (1996) 1.51
AIDS and i.v. drug use. Science (1989) 1.51
An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis (1996) 1.51